• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
    • Cancer Genetic Risk Assessment Program
    • Second Opinion for Cancer
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • PSMA Risk Calculator
    • SPORE In Prostate Cancer
    • External Funding Opportunities
    • Webinars / Videos
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Study Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Health Plans and Financial Matters
    • Maps and Directions
    • myUCLAhealth
    • Patient Testimonials
    • Preparing for Surgery
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • SPORE Lectures
    • External Funding Opportunities
  • Expert Team
    • Board of Directors
    • Medical Oncology
    • Nuclear Medicine
    • Pathology
    • Radiation Oncology
    • Radiology
    • Urologic Oncology
    • Research Faculty
    • Emeritus Faculty
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Clinical Trials

Clinical Trials

Clinical Trials

  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  1. Home
  2. Institute of Urologic Oncology
  3. Clinical Trials
  4. A Registry for Men with Advanced Prostate Cancer

A Registry for Men with Advanced Prostate Cancer

Share this

IRONMAN – International Registry for Men with Advanced Prostate Cancer

Lay Title:A Registry for Men with Advanced Prostate Cancer
Technical Title: IRONMAN – International Registry for Men with Advanced Prostate Cancer

Disease Type:(1) Metastatic hormone-sensitive prostate cancer, (2) non-metastatic castration-resistant prostate cancer, or (3) metastatic castration-resistant prostate cancer

Basic information: The purpose of this research is to create a registry of data about advanced prostate cancer. This data will be used to learn more about advanced prostate cancer treatments (such as their outcomes and how they are used differently internationally) and the experience and quality of life of patients with advanced prostate cancer. The study also aims to identify clinical and molecular disease subtypes to help researchers understand how different people respond to different cancer treatments. 

Research Procedures (not a complete list): If you agree to participate in this study, the research team will collect data from your medical records. You will also be asked to complete questionnaires about your symptoms, quality of life, ability to function, medications, ability to work, and financial concerns due to your diagnosis. The study team will also take blood samples at enrollment, each time you change cancer treatment, and at one year follow-up. This blood will be used for biomarker testing, which can help researchers understand how the body responds to different cancer treatments.  

Eligibility Criteria (not a complete list):
Inclusion Criteria:

  • One of the following diagnoses:
    • Metastatic hormone-sensitive prostate cancer (mHSPC) with no more than 90 days of active treatment
    • Castration-resistant prostate cancer, with no more than 6 weeks of active treatment

Exclusion Criteria:

  • None

For More Detailed Information, Contact:

  • Allan Pantuck, MD, Principal Investigator, Professor of Urology
  • Sara R., Study Coordinator, (310) 794-2877

Read more about this study (NCT03151629) on ClinicalTrials.gov.

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest